RNK-05047 is under clinical development by Ranok Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RNK-05047’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RNK-05047 overview

RNK-05047 is under development for the treatment of advanced solid tumor cancers and diffuse large B-cell lymphoma. It is acts by targeting BRD4 protein. It is developed based on chaperone-mediated protein degradation/degrader (CHAMP) technology. It is administered through intravenous route.

Ranok Therapeutics overview

Ranok Therapeutics is a pharmaceuticals company focuseing on patients suffering from cancer and other serious diseases. Ranok Therapeutics is headquartered in Hangzhou, Zhejiang, China.

For a complete picture of RNK-05047’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.